Stelara is one of many top-selling medicines that will face competition from copycat versions this decade, including a large number of biologic drugs.
AbbVie’s anti-inflammatory medicine Humira — sales of which topped $21 billion in 2022 — has been a top target for biosimilars, with 10 copycat versions cleared by the FDA. One of those medicines is Alvotech and Teva’s Simlandi, which won approval in February along with interchangeable status, which means pharmacists can directly substitute the drug for Humira.
